Table 1

List of insulins procured in the national volume-based procurement, 2021

No	Active ingredient	Generation	Bidding group	Type	NRDL category	Biosimilars approved by NMPA
1	Human insulin	Second	Mealtime human	Human	A	Yes
2	Isophane protamine human insulin	Second	Basal human	Human	A	Yes
3	Mixed protamine human insulin	Second	Premixed human	Human	A	Yes
4	Insulin degludec	Third	Long-acting basal analogue	Analogue	B	No
5	Insulin detemir	Third	Long-acting basal analogue	Analogue	B	No
6	Insulin glargine	Third	Long-acting basal analogue	Analogue	B	Yes
7	Insulin glulisine	Third	Rapid-acting analogue	Analogue	B	No
8	Insulin lispro	Second	Rapid-acting analogue	Analogue	B	Yes
9	Insulin aspart	Second	Rapid-acting analogue	Analogue	B	Yes
10	Premixed insulin aspart	Third	Premixed analogue	Analogue	B	Yes
11	Mixed protamine zinc human insulin lispro	Third	Premixed analogue	Analogue	B	Yes

NMPA, National Medical Products Administration; NRDL, National Reimbursement Drug List.